Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype

Won Jung Koh, Seong Mi Moon, Su Young Kim, Min Ah Woo, Seonwoo Kim, Byung Woo Jhun, Hye Yun Park, Kyeongman Jeon, Hee Jae Huh, Chang Seok Ki, Nam Yong Lee, Myung Jin Chung, Kyung Soo Lee, Sung Jae Shin, Charles L. Daley, Hojoong Kim, O. Jung Kwon

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The effect of the clinical phenotype of Mycobacterium avium complex (MAC) lung disease on treatment outcome and redevelopment of nontuberculous mycobacterial (NTM) lung disease after treatment completion has not been studied systematically.We evaluated 481 treatment-naïve patients with MAC lung disease who underwent antibiotic treatment for ≥12 months between January 2002 and December 2013.Out of 481 patients, 278 (58%) had noncavitary nodular bronchiectatic (NB) disease, 80 (17%) had cavitary NB disease and 123 (25%) had fibrocavitary disease. Favourable outcome was higher in patients with noncavitary disease (88%) than in patients with cavitary disease (76% for fibrocavitary and 78% for cavitary NB disease; p<0.05). Cavitary disease was independently associated with unfavourable outcomes (p<0.05). Out of 402 patients with favourable outcomes, 118 (29%) experienced redevelopment of NTM lung disease, with the same MAC species recurring in 65 (55%) patients. The NB form was an independent risk factor for redevelopment of NTM lung disease (p<0.05). In patients with recurrent MAC lung disease due to the same species, bacterial genotyping revealed that 74% of cases were attributable to reinfection and 26% to relapse.Treatment outcomes and redevelopment of NTM lung disease after treatment completion differed by clinical phenotype of MAC lung disease.

Original languageEnglish
JournalThe European respiratory journal
Volume50
Issue number3
DOIs
Publication statusPublished - 2017 Sep 1

Fingerprint

Mycobacterium avium Complex
Lung Diseases
Phenotype
Therapeutics
Anti-Bacterial Agents
Recurrence

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Koh, W. J., Moon, S. M., Kim, S. Y., Woo, M. A., Kim, S., Jhun, B. W., ... Kwon, O. J. (2017). Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. The European respiratory journal, 50(3). https://doi.org/10.1183/13993003.02503-2016
Koh, Won Jung ; Moon, Seong Mi ; Kim, Su Young ; Woo, Min Ah ; Kim, Seonwoo ; Jhun, Byung Woo ; Park, Hye Yun ; Jeon, Kyeongman ; Huh, Hee Jae ; Ki, Chang Seok ; Lee, Nam Yong ; Chung, Myung Jin ; Lee, Kyung Soo ; Shin, Sung Jae ; Daley, Charles L. ; Kim, Hojoong ; Kwon, O. Jung. / Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. In: The European respiratory journal. 2017 ; Vol. 50, No. 3.
@article{6debe0e950bb4706baae56c4054522b7,
title = "Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype",
abstract = "The effect of the clinical phenotype of Mycobacterium avium complex (MAC) lung disease on treatment outcome and redevelopment of nontuberculous mycobacterial (NTM) lung disease after treatment completion has not been studied systematically.We evaluated 481 treatment-na{\"i}ve patients with MAC lung disease who underwent antibiotic treatment for ≥12 months between January 2002 and December 2013.Out of 481 patients, 278 (58{\%}) had noncavitary nodular bronchiectatic (NB) disease, 80 (17{\%}) had cavitary NB disease and 123 (25{\%}) had fibrocavitary disease. Favourable outcome was higher in patients with noncavitary disease (88{\%}) than in patients with cavitary disease (76{\%} for fibrocavitary and 78{\%} for cavitary NB disease; p<0.05). Cavitary disease was independently associated with unfavourable outcomes (p<0.05). Out of 402 patients with favourable outcomes, 118 (29{\%}) experienced redevelopment of NTM lung disease, with the same MAC species recurring in 65 (55{\%}) patients. The NB form was an independent risk factor for redevelopment of NTM lung disease (p<0.05). In patients with recurrent MAC lung disease due to the same species, bacterial genotyping revealed that 74{\%} of cases were attributable to reinfection and 26{\%} to relapse.Treatment outcomes and redevelopment of NTM lung disease after treatment completion differed by clinical phenotype of MAC lung disease.",
author = "Koh, {Won Jung} and Moon, {Seong Mi} and Kim, {Su Young} and Woo, {Min Ah} and Seonwoo Kim and Jhun, {Byung Woo} and Park, {Hye Yun} and Kyeongman Jeon and Huh, {Hee Jae} and Ki, {Chang Seok} and Lee, {Nam Yong} and Chung, {Myung Jin} and Lee, {Kyung Soo} and Shin, {Sung Jae} and Daley, {Charles L.} and Hojoong Kim and Kwon, {O. Jung}",
year = "2017",
month = "9",
day = "1",
doi = "10.1183/13993003.02503-2016",
language = "English",
volume = "50",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "3",

}

Koh, WJ, Moon, SM, Kim, SY, Woo, MA, Kim, S, Jhun, BW, Park, HY, Jeon, K, Huh, HJ, Ki, CS, Lee, NY, Chung, MJ, Lee, KS, Shin, SJ, Daley, CL, Kim, H & Kwon, OJ 2017, 'Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype', The European respiratory journal, vol. 50, no. 3. https://doi.org/10.1183/13993003.02503-2016

Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. / Koh, Won Jung; Moon, Seong Mi; Kim, Su Young; Woo, Min Ah; Kim, Seonwoo; Jhun, Byung Woo; Park, Hye Yun; Jeon, Kyeongman; Huh, Hee Jae; Ki, Chang Seok; Lee, Nam Yong; Chung, Myung Jin; Lee, Kyung Soo; Shin, Sung Jae; Daley, Charles L.; Kim, Hojoong; Kwon, O. Jung.

In: The European respiratory journal, Vol. 50, No. 3, 01.09.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype

AU - Koh, Won Jung

AU - Moon, Seong Mi

AU - Kim, Su Young

AU - Woo, Min Ah

AU - Kim, Seonwoo

AU - Jhun, Byung Woo

AU - Park, Hye Yun

AU - Jeon, Kyeongman

AU - Huh, Hee Jae

AU - Ki, Chang Seok

AU - Lee, Nam Yong

AU - Chung, Myung Jin

AU - Lee, Kyung Soo

AU - Shin, Sung Jae

AU - Daley, Charles L.

AU - Kim, Hojoong

AU - Kwon, O. Jung

PY - 2017/9/1

Y1 - 2017/9/1

N2 - The effect of the clinical phenotype of Mycobacterium avium complex (MAC) lung disease on treatment outcome and redevelopment of nontuberculous mycobacterial (NTM) lung disease after treatment completion has not been studied systematically.We evaluated 481 treatment-naïve patients with MAC lung disease who underwent antibiotic treatment for ≥12 months between January 2002 and December 2013.Out of 481 patients, 278 (58%) had noncavitary nodular bronchiectatic (NB) disease, 80 (17%) had cavitary NB disease and 123 (25%) had fibrocavitary disease. Favourable outcome was higher in patients with noncavitary disease (88%) than in patients with cavitary disease (76% for fibrocavitary and 78% for cavitary NB disease; p<0.05). Cavitary disease was independently associated with unfavourable outcomes (p<0.05). Out of 402 patients with favourable outcomes, 118 (29%) experienced redevelopment of NTM lung disease, with the same MAC species recurring in 65 (55%) patients. The NB form was an independent risk factor for redevelopment of NTM lung disease (p<0.05). In patients with recurrent MAC lung disease due to the same species, bacterial genotyping revealed that 74% of cases were attributable to reinfection and 26% to relapse.Treatment outcomes and redevelopment of NTM lung disease after treatment completion differed by clinical phenotype of MAC lung disease.

AB - The effect of the clinical phenotype of Mycobacterium avium complex (MAC) lung disease on treatment outcome and redevelopment of nontuberculous mycobacterial (NTM) lung disease after treatment completion has not been studied systematically.We evaluated 481 treatment-naïve patients with MAC lung disease who underwent antibiotic treatment for ≥12 months between January 2002 and December 2013.Out of 481 patients, 278 (58%) had noncavitary nodular bronchiectatic (NB) disease, 80 (17%) had cavitary NB disease and 123 (25%) had fibrocavitary disease. Favourable outcome was higher in patients with noncavitary disease (88%) than in patients with cavitary disease (76% for fibrocavitary and 78% for cavitary NB disease; p<0.05). Cavitary disease was independently associated with unfavourable outcomes (p<0.05). Out of 402 patients with favourable outcomes, 118 (29%) experienced redevelopment of NTM lung disease, with the same MAC species recurring in 65 (55%) patients. The NB form was an independent risk factor for redevelopment of NTM lung disease (p<0.05). In patients with recurrent MAC lung disease due to the same species, bacterial genotyping revealed that 74% of cases were attributable to reinfection and 26% to relapse.Treatment outcomes and redevelopment of NTM lung disease after treatment completion differed by clinical phenotype of MAC lung disease.

UR - http://www.scopus.com/inward/record.url?scp=85036543421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036543421&partnerID=8YFLogxK

U2 - 10.1183/13993003.02503-2016

DO - 10.1183/13993003.02503-2016

M3 - Article

C2 - 28954780

AN - SCOPUS:85036543421

VL - 50

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 3

ER -